Discussion
postoperative thromboembolic
THROMBOEMBOLIC EVENT, ADVERSE EVENTS, HEPARIN-INDUCED THROMBOCYTOPENIA, POSTOPERATIVE THROMBOSIS, BSE
Our randomized clinical trial showed that there was no statistically significant difference between BE and BSE groups in the occurrence of postoperative thromboembolic events. There was no statistically significant difference between BE and BSE groups regarding incident heparin-induced thrombocytopenia. No predictors factors of postoperative thrombosis after digestive oncology surgery were identified.Our RCT is the first to compare BE with BSE on an asymptomatic thromboembolic event as the primary end point, while controlling for adverse events.A biosimilar drug is a biological drug with the same qualitative and quantitative composition in active substance and the same pharmaceutical form as a reference biological drug. A biosimilar is not regarded as a generic of a biological medicine [A systematic review, reported by Mielke et al in 2018 [As concerns Generic, several randomized controlled trials (RCT) [As concerns biosimilar, two RCTs compared new biosimilar treatment of Enoxaparin to a reference treatment [In Tunisia, the same BSE, evaluated in our RCT, has already been the subject of two non-comparative studies concerning patients who underwent a total hip replacement [The cost difference between BSE ($2.85/day) and BE ($4.5/day) is assessed over a 30-day period. Our research demonstrates that BSE offers a significant cost advantage, with daily savings of $1.65 per patient and a percentage difference of approximately -36.67%. These highlight the economic benefits associated with choosing the BSE option, reinforcing its potential as a cost-effective alternative in clinical practice.